

# ANAGENICS

## ASX ANNOUNCEMENT

### ANAGENICS LIMITED (ASX: AN1) – RESULTS FROM INSTITUTIONAL ENTITLEMENT OFFER (ANREO)

---

- **Accelerated Non-Renounceable Entitlement Offer (ANREO) seeking to raise up to \$3.2 million**
- **1 new share for 1.3748 shares held at \$0.022 offer price**
- **Successful completion from institutional and professional investors Hancock and Gore Limited**

**SYDNEY, Thursday, 16<sup>th</sup> February 2023**

Anagenics Limited (**Anagenics** or the **Company**) is pleased to advise that the Institutional Entitlement Offer (**IEO**) under the ANREO (as announced on 14 February 2023) closed on 15 February 2023 with existing substantial shareholder Hancock & Gore Limited (**HNG**) and its related party H&G High Conviction Limited taking up their full entitlement, raising a total of \$614,800 (before transaction costs). Settlement of the New Shares under the IEO is expected to occur on 23 February 2023 and the allotment of the 27,945,470 New Shares on 24 February 2023. This represented full take up of the shares offered under the IEO.

Anagenics once again acknowledges and thanks HNG for the financial support it has shown during this ANREO, particularly its commitment to fully underwrite both retail and institutional components, thereby demonstrating their belief in the Company.

The retail component of the rights offer will commence from Tuesday, 21 February 2023 and is expected to close at 5.00pm (Sydney time) on Monday, 6 March 2023. The use of the total expected proceeds from both components of the rights issue has been outlined in detail per the Investor Presentation released to the ASX on 14 February 2023. These are expected to be as allocated as follows:

1. Potential M&A acquisition (\$1.5M)
2. Repayment of BLC deferred consideration obligation to HNG (\$1.1M)
3. Investment in BLC via growth capital (\$0.3M)
4. Cost of offer (\$0.3M)

CEO Matthew Dudek said: “On behalf of the Directors, I encourage all eligible retail investors to consider this investment opportunity and thank them for their ongoing support.”

Approved for release by the Independent Board Committee of Anagenics Limited.

Contact:

**Matthew Dudek**  
**CEO**  
**+61 455 503 790**

# ANAGENICS

**info@anagenics.com**

## **Anagenics Limited (ASX: AN1)**

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics' wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see [www.anagenics.com](http://www.anagenics.com) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

## **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.